ProfileGDS5678 / 1425463_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 9% 9% 9% 9% 9% 11% 9% 9% 9% 9% 9% 9% 9% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.235149
GSM967853U87-EV human glioblastoma xenograft - Control 22.21329
GSM967854U87-EV human glioblastoma xenograft - Control 32.218189
GSM967855U87-EV human glioblastoma xenograft - Control 42.181349
GSM967856U87-EV human glioblastoma xenograft - Control 52.172939
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3362511
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.233769
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.194179
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.189629
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.206849
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.199119
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.192639
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.204719
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.203529